CILcare

Preclinical and clinical evaluation services designed to test drug candidates and devices for ototoxicity, inner-ear safety, and auditory function preservation.

Ex vivo assay on cochlear explants to quantify and qualify damage to cochlear structures, assess efficiency and mechanism of action of drug candidates, and allow rigorous dose selection.

An in vitro screening model using the HEI-OC1 cell line for studying otoprotective properties and identifying potential ototoxic compounds at an early phase.

Advanced clinical auditory biomarker research and measurement services to support the development of innovative therapies for hearing disorders, ototoxicity, and related conditions.

Acute and chronic models in rats, guinea pigs, and mice for evaluating ototoxic insults and testing protective compounds.

A cutting-edge platform for precise evaluation of hearing function, offering non-invasive and translational measurements calibrated for high-throughput testing in animal models.

An AI-driven auditory analytics platform that translates auditory measurements and biomarkers into digital auditory signatures using proprietary algorithms and deep learning for early diagnosis and precision medicine.

High-level cochlear assessment technique combining precision technology to deliver robust and qualitative cochleogram data for non-GLP or GLP studies.

Preclinical pharmacokinetic (PK) studies to assess the bioavailability and kinetic profile of drug candidates for hearing loss and tinnitus in the inner ear.

Preclinical model designed to study auditory neuropathy characterized by impaired transmission of sound and damage to the auditory nerve.

Specialized services and physicochemical profiling for developing optimized formulations for local inner ear and transtympanic drug delivery.

Robust in vivo models and testing services provided by CILcare to assess the efficacy and safety of cochlear implants, surgical approaches, and drug-eluting electrodes.

Zebrafish model for assessing ototoxicity, evaluating otoprotection, and conducting large-scale compound screenings utilizing mechanosensory neuromasts.

Comprehensive histopathology and immunochemistry services for the external, middle, and inner ear including paraffin slide preparation and cytocochleogram.

Examination of the eardrum's surface using a video endoscope with a miniature camera to identify irregularities, perforations, or pathology for tolerance and GLP ototoxicity studies.

Assessment allowing observation of the integrity and appearance of the eardrum and ossicles, presence of formulation residues, and evaluation of auditory function or potential drug ototoxicity.

Acute rat model enabling short in vivo studies with low variability for monitoring physiological changes related to tinnitus.

Advanced imaging services including Scanning Electron Microscopy (SEM), optic microscopy, confocal fluorescence microscopy, and Transmission Electron Microscopy (TEM).

Gap detection test (Gap Prepulse Inhibition of the Acoustic Startle Reflex) used to assess changes in auditory perception and response to detect tinnitus in animal models.

Prepulse inhibition test combined with GPIAS for a comprehensive approach to detect tinnitus and hearing loss, measuring sensorimotor gating in rodents.

Assessing protein expression in fluids or tissues using ELISA or multiplex methods.

Assessment of liver and kidney toxicity, signs of inflammation, and metabolic indicators.

Analyzing transcriptome expression (RNA sequencing) or specific gene expression in fluids or tissues.

Histopathology, immunochemistry, and immunofluorescence services for various extra-otic organs such as liver, kidney, spleen, brain, and spinal cord.

Objective measurement assessing the mobility of the tympanic membrane and sound transmission into the middle ear using sound and air pressure.